The estimated Net Worth of Geoffrey Michael Glass is at least $805 Mille dollars as of 10 August 2023. Geoffrey Glass owns over 14,000 units of Avadel Pharmaceuticals plc stock worth over $805,350 and over the last 6 years Geoffrey sold AVDL stock worth over $0.
Geoffrey has made over 5 trades of the Avadel Pharmaceuticals plc stock since 2019, according to the Form 4 filled with the SEC. Most recently Geoffrey bought 14,000 units of AVDL stock worth $187,600 on 10 August 2023.
The largest trade Geoffrey's ever made was buying 45,000 units of Avadel Pharmaceuticals plc stock on 1 June 2022 worth over $96,300. On average, Geoffrey trades about 6,050 units every 85 days since 2018. As of 10 August 2023 Geoffrey still owns at least 59,000 units of Avadel Pharmaceuticals plc stock.
You can see the complete history of Geoffrey Glass stock trades at the bottom of the page.
Geoffrey's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.
Over the last 8 years, insiders at Avadel Pharmaceuticals plc have traded over $7,791,038 worth of Avadel Pharmaceuticals plc stock and bought 775,568 units worth $4,366,224 . The most active insiders traders include Healthcare Master Fund Ltd ..., Kevin Broadfin Capital, Llc... e Naseem Amin. On average, Avadel Pharmaceuticals plc executives and independent directors trade stock every 43 days with the average trade being worth of $381,436. The most recent stock trade was executed by Thomas S Mchugh on 16 January 2024, trading 2,000 units of AVDL stock currently worth $29,000.
avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.
Avadel Pharmaceuticals plc executives and other stock owners filed with the SEC include: